Fosun Pharma announces HK$1 billion H-share repurchase plan

Fosun Pharma has announced a plan to repurchase its H-shares for an aggregate amount of up to HK$1 billion. The company stated that the repurchase aims to respond to market concerns and demonstrate confidence in its intrinsic value. The repurchased shares will be either cancelled or held as treasury shares.

The repurchase will be primarily funded by proceeds from the sale of a stake in Gland Pharma. Fosun Pharma Industrial Pte Ltd sold approximately 4.55% of its holdings in the Hyderabad-based Gland Pharma through multiple block deals on the Bombay Stock Exchange (BSE), totaling roughly US$294 million (approximately ₹2,121 crore).

Following the sale, Fosun Pharma’s shareholding in Gland Pharma has decreased from 51.77% to 47.22%, though it remains the controlling shareholder. The capital raised is intended for research and development, share repurchases, and the repayment of interest-bearing debts.

In the first half of 2026, Fosun Pharma reported revenue of RMB 20,442 million, a 4.75% year-on-year increase, and a net profit attributable to shareholders of RMB 1,144 million, up 19.09% year-on-year.